6 research outputs found

    Baseline Characteristics at Initiation of Tocilizumab Therapy in Patients Completing 6 Months of Treatment.

    No full text
    <p>Results are presented as the mean ± standard deviation, median (minimum, maximum), or number of cases with percentages. CDAI: clinical disease activity index; CI: confidence interval; d: difference; LEF: leflunomide; MTX: methotrexate; SDAI: simplified disease activity index.</p><p>Baseline Characteristics at Initiation of Tocilizumab Therapy in Patients Completing 6 Months of Treatment.</p

    Supplemental Material - Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice

    No full text
    Supplemental Material for Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice by Beatriz Frade-Sosa, Tarek Carlos Salman-Monte, Javier Narváez, Irene Peralta, Sebastian Sandoval, Berta Magallares, Sergi Heredia, Nuria Sapena, Anne Riveros-Frutos, Alejandro Olivé, Hector Corominas, Josefina Cortés-Hernández, and Jose A Gómez-Puerta in Lupus</p
    corecore